| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Novartis Institute for Biomedical Research, LSB 3517, Summit, New Jersey 07901
 |
ABSTRACT |
|---|
 TOP
 ABSTRACT
 INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
The incretin glucagon-like
peptide-1 (GLP-1)-(7---36) amide is an important factor in prandial
glucose homeostasis. Findings that GLP-1 is rapidly inactivated led to
the hypothesis that the target of GLP-1 is close to the site of
release. To investigate whether the target tissue is located in the
hepatoportal system, we administered GLP-1 with glucose into the portal
vein of rats and compared this with peripheral GLP-1 administration
(jugular vein) and studied the effects of blockers of the nervous
system. Portal GLP-1 augmented the insulin response to a portal glucose bolus by 81% (P < 0.01) and markedly improved the
glucose disposal rate (P < 0.05). Peripheral
administration of GLP-1 produced a similar augmentation of the insulin
response (88%) and of the glucose disposal rate. However, only the
effect of portal GLP-1 on insulin secretion was blocked by the
ganglionic blocker chlorisondamine. The data suggest that prandial
-cell stimulation by GLP-1 is evoked via a neural reflex triggered
in the hepatoportal system. Because absorbed nutrients and GLP-1 first
appear in the portal system, this mechanism may constitute a major
pathway of GLP-1 action during meals.
glucagon-like peptide-1; incretin; autonomic nervous system
| |
INTRODUCTION |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
GLUCAGON-LIKE
PEPTIDE-1 (GLP-1) is a potent incretin that is released from the
distal small intestine in response to absorbed nutrients. Its primary
function is believed to be the sensitization of the -cells in the
islets of Langerhans to stimulation by glucose. GLP-1 is released by
the L cells in the intestinal tract as GLP-1-(7---36) amide, which is
derived from proglucagon (8, 10). GLP-1 is rapidly
inactivated by the ubiquitous enzyme dipeptidyl peptidase IV (DPP-IV)
(4). This enzyme clips two penultimate amino acids and
renders GLP-1-(9---36) amide, which is inactive or even has antagonistic properties, depending on the tissue (16). The
inactivation of GLP-1 by DPP-IV is very rapid, leading to a half-life
of the active peptide of ~1-1.5 min in pigs, thereby exceeding
the cardiac output rate by a factor of 2 (11).
Furthermore, it has recently been demonstrated that 50% of
GLP-1-(7---36) amide that is released from the intestinal L cells is
degraded in the surrounding capillaries (9). Thus the
active GLP-1-(7---36) amide may never reach the pancreas. Therefore, we
hypothesized that GLP-1 released by the L cells may trigger an
intermediary mechanism locally that relays the signal to the pancreas.
A recent study reported that GLP-1 administered via the hepatic portal
vein will increase the firing rate of hepatic afferent nerves and, in a
reflex manner, also increase the activity of the pancreatic vagal
fibers (12). This led us to hypothesize that the hepatic
portal system may constitute one site of GLP-1 action. The goal of this
study was to investigate whether an indirect mechanism triggered in the
hepatoportal circulatory system may be involved in the stimulation of
insulin secretion by endogenously secreted GLP-1. To that end, we
mimicked the appearance of glucose and GLP-1 in the portal system and
studied whether the augmentation of the insulin response would be
affected by specific blockade of parts of the autonomic nervous system.
We further studied whether administration of GLP-1 to the pancreas via
the jugular vein would be similarly affected by autonomic blockade.
| |
METHODS |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Animals and Surgery. Male Sprague-Dawley rats (Hilltop, PA) were maintained on normal light cycle (lights on 6:00 AM to 6:00 PM) with ad libitum access to tap water and standard rodent chow (Purina Labs, Richmond, IN). The animals were aseptically implanted with a Silastic catheter in the right jugular vein under ketamine-Rompun-acepromazine anesthesia. The catheter was externalized in the nape of the neck and was filled with a solution of heparin and polyvinylpyrrolidone. A second Silastic catheter was implanted into the hepatic portal vein ~8 mm caudal of the liver. This method has been described in detail previously (17). The animals were allowed to recover until they reached their preoperative weight again, but a minimum of 5 days was allowed even when weight recovery was achieved earlier.
Reagents. GLP-1-(7---36) amide was obtained from Bachem (Torrance, CA). The ganglionic blocker chlorisondamine (CS) chloride (Ciba Pharmaceuticals, Summit, NJ) was administered at 3 mg/kg as an intravenous (jugular vein) bolus. Methyl atropine (atropine methyl bromide supplied by Sigma, St. Louis, MO), a peripherally acting muscarinic blocker, was injected into the jugular vein at 0.5 mg/kg. Glucose was administered into the portal vein at 500 mg/kg. All doses were given as separate injections.
Protocols.
The animals were fasted starting at 5:00 PM on the day before the
experiment. At t = 
30 min on the day of the
experiment, the cannulas were connected to sampling tubing. At
t = 0 and t = 30 min, a 200-µl bolus
of vehicle (saline with 1% BSA) or GLP-1 (10 pmol/kg) was injected
into the portal or jugular vein. Glucose (500 mg/kg, 1 ml/kg) was
injected into the portal vein at t = 30 min,
immediately before the second vehicle or GLP-1 administration. In some
experiments, a ganglionic blocker (CS-HCl, 3 mg/kg, t = 30 min) or a peripheral muscarinic blocker (0.5 mg/kg methyl atropine, t = 10 and t = 20 min) was
administered intravenously before portal injections.
10 and
t = 0 min, and additional samples were withdrawn over
90 min. All samples were replaced by donor blood containing citrate and
sodium citrate as anticoagulant. Blood samples were collected into
chilled Eppendorf tubes containing EDTA and trasylol to achieve final
concentrations of 2.5 mg EDTA and 1,000 kallikrein inhibitory units of
trasylol per mililiter of blood. Samples were centrifuged, and
plasma was stored at 20°C until analyses. The protocol was reviewed
and approved by the Novartis Animal Care and Use Committee.
Plasma analyses. Plasma glucose was analyzed using a modified Sigma Diagnostics glucose oxidase kit (Sigma). Plasma immunoreactive insulin levels were assayed by a double-antibody RIA method using a specific anti-rat insulin antibody from Linco Research (St Louis, MO). The assay has a lower limit of detection of 30 pmol/l with intra- and interassay variations of <5%.
Data are expressed as means ± SE. Incremental integrated areas under the curve were calculated by the trapezoidal rule. Statistical analysis was performed by t-test. All statistical significance reflects two-tailed testing unless stated otherwise.| |
RESULTS |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Portal GLP-1 (10 pmol/kg, n = 9) augmented the
integrated insulin response to a portal glucose bolus (Fig.
1A). This near doubling of the
insulin response to portal glucose (Table
1) was in marked contrast to the
relatively minor stimulation of insulin secretion induced by portal
GLP-1 alone (Fig. 1B). Administration of GLP-1 into the
right atrium together with the portal glucose load was equally
efficacious in augmenting the insulin response (Fig.
2A).
Indeed, portal and jugular vein-injected GLP-1 had nearly identical
effects on the glucose excursion after the portal glucose challenge
(Fig. 2B). This suggests that the increased glucose disposal
rate found after GLP-1 administration (Table 1) may be a consequence of
the augmented insulin response. The only difference found between
groups of animals receiving GLP-1 in the portal vein versus the jugular
vein was observed when the peptide was administered in the absence of
the glucose load. The insulin response to GLP-1 alone was much larger
when GLP-1 was administered via the jugular vein than when administered
via the portal vein (Fig. 2C). This finding supports the
expectation that less GLP-1 would reach the pancreas after portal
administration than after injection into the jugular vein. To reconcile
the profound augmentation of glucose-induced insulin secretion after
portal administration, we hypothesized that the effects of portal GLP-1 are, at least in part, mediated by the autonomic nervous system. Therefore, we repeated the study after complete ganglionic blockade with CS. Pretreatment with CS reduced the insulin response to portal
GLP-1 and glucose to that seen with portal glucose alone (Fig.
3A). Concomitantly, ganglionic
blockade reduced the glucose disappearance rate (Table 1).
|
|
|
|
Administration of the muscarinic blocker methyl atropine did not affect the augmentation of the insulin response to portal glucose by portal GLP-1 (Table 1). The glucose disappearance rates in the atropine-treated animals displayed a large degree of variability, which makes it impossible to ascertain whether there was an effect (Table 1).
In contrast to the actions of ganglionic blockade on the effects of
portal GLP-1, the potentiation of insulin secretion by GLP-1 given in
the jugular vein was not affected by CS (Fig. 3B and Table
1). Ganglionic blockade alone did not affect the insulin response to
portal glucose (Fig. 4)
|
| |
DISCUSSION |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
The purpose of this study was to investigate whether GLP-1
administered into the hepatic portal vein can augment the insulin response to a portal glucose load mimicking glucose appearing from
absorbed carbohydrates. Furthermore, this study investigated whether
this augmentation of insulin secretion is direct or indirect in nature.
The results demonstrate that the augmentation of the insulin response
to portal glucose is profound and much larger than the stimulation by
portal GLP-1 administration in the absence of exogenous glucose. This
finding is in accordance with the generally accepted view that GLP-1
sensitizes -cells to stimulation by glucose (7, 19).
However, the prevention of the augmentation of the portal GLP-1-induced
insulin response by ganglionic blockade suggests that portal GLP-1
triggers a nervous mechanism. We further conclude that the failure to
inhibit the portal GLP-1-induced augmentation of insulin secretion by
the peripherally acting muscarinic blocker methyl atropine demonstrates
that this mechanism does not involve the classic parasympathetic
nervous system, the effects of which are mediated by acetylcholine
acting on muscarinic receptors. The data suggest that the effect of
portal GLP-1 is mediated by nonmuscarinic parasympathetic activation or
suppression of the sympathetic inhibitory tone.
We hypothesize that GLP-1 affects afferent nerves in the hepatoportal bed that lead to altered nervous control of the islets of Langerhans. Indeed, changes in firing rate of hepatic afferent and pancreatic efferent nerves have been demonstrated after administration of GLP-1 in the hepatoportal system (12). The slow and long-lasting nature of the effects in those studies may have been a consequence of the use of anesthesia and contrasts with the speed of the augmentation in the present study. The fact that the potentiation of the insulin response in the current study was discernible within 1 min after administration of glucose and GLP-1 suggests a nervous-nervous rather than nervous-humoral reflex loop.
The afferent signal is most likely transmitted by the afferent vagus
nerve, considering the abundance of these fibers in this region.
Furthermore, the vagal system has been demonstrated to be very
sensitive to many gastrointestinal hormones and nutrients (13,
15). Several possibilities can be considered for the efferent
part of the loop. Muscarinic parasympathetic stimulation of -cells
evokes a very strong secretory effect (in the presence of glucose) and
has been shown to be part of the adaptation of the body to a number of
metabolic challenges, including prolonged stimulation by glucose
(3, 18). The lack of effect of methyl atropine rules out
this hypothesis. Alternatively, the sympathetic nervous system may be
involved in this process. Sympathetic nervous stimulation of the
endocrine pancreas generally results in inhibition of insulin secretion
(1), and the observed effects in the current study would
suggest reduced sympathetic activity to the islets of Langerhans. This
possibility remains to be investigated. However, the involvement of
nonclassical neurotransmitters, e.g., neuropeptides, as yet an
alternative explanation cannot be discarded. A number of peptides are
potent cotransmitters in autonomic nerves in the pancreas
(2) and may be responsible for the observed phenomenon.
It is likely that ganglionic blockade, or the altering of the balance between sympathetic and parasympathetic tone during atropine treatment, has some effect on circulatory parameters. However, the lack of effect of ganglionic blockade on the insulin response and glucose excursion after glucose administration without GLP-1 is evidence that any potential circulatory effect did not affect the pancreatic response. The lack of effect of ganglionic blockade on the stimulation of insulin secretion by glucose alone further rules out the possibility that portal glucose triggers a reflex that relies on the autonomic nervous system under the conditions of this experiment.
GLP-1 is one of the most potent stimulators of glucose-induced insulin
secretion. Numerous studies have investigated direct effects of GLP-1
on -cells both in vitro and during continuous infusions in vivo.
Endogenous GLP-1 is limited in its action by very rapid inactivation
under influence of DPP-IV, which cleaves two NH2-terminal
amino acids, thereby rendering the hormone inactive (for its -cell
effect) (4). Fifty percent of the GLP-1-(7---36) amide
released from the L cells is estimated to be inactivated in the
capillary bed surrounding these cells (9). Furthermore, single pass through the liver inactivates a large fraction of the
remaining active GLP-1 (>40%) (5). Thus these two
processes together with inactivation in the circulatory system and in
other organs can be expected to inactivate or remove most of the GLP-1 released from the intestine before the peptide can reach the pancreas in the active form.
Interestingly, peripheral administration of GLP-1 via the jugular vein also potentiated the insulin response to portal glucose. However, this response was not affected by ganglionic blockade. The larger insulin response to jugular GLP-1 than to portal GLP-1 in the absence of the glucose load is consistent with the expectation that more GLP-1 would reach the islets of Langerhans in the active form after administration into the jugular vein. Thus it appears that GLP-1 can affect insulin secretion both directly and via a nervous mechanism triggered in the hepatoportal system.
We conclude that portal GLP-1 greatly affects handling of a portal
glucose load. This effect appears to be mediated by augmented insulin
release. The data suggest that -cell stimulation by portal GLP-1 is
evoked via a neural reflex that may be triggered in the liver and is
nonmuscarinic in nature. Because absorbed nutrients and GLP-1 first
appear in the portal system, this mechanism may constitute a major
pathway of GLP-1 action during meals. The effects of GLP-1
administration into the jugular vein do not appear to be mediated by
the nervous system, suggesting that portal and peripheral GLP-1 may
exert their effects on insulin secretion through different mechanisms.
Perspectives
The physiological significance of the redundancy between portal and direct augmentation of insulin secretion by GLP-1 is unclear at present but may reflect different regulatory mechanisms during large and small meals. A small meal triggering a small, transient release of GLP-1 may only be sufficient to trigger the nervous effects in the hepatoportal system. This would rapidly initiate the insulin response accelerating the transition of the liver from glucose production to glucose uptake (6). Only larger meals or slowly absorbed nutrients may lead to GLP-1 release in sufficient quantity and duration to affect the-cells directly. Alternatively, it can be hypothesized
that the GLP-1 receptors in the hepatoportal system and on -cells
constitute parts of a nervous loop mediating the endocrine response to
endogenously released GLP-1. The well-documented insulinotropic action
of GLP-1 administered into the general circulation would then exert its effects through receptors normally responding to GLP-1 released by
autonomic nerves. The support for this hypothesis is currently slim,
and a recent report suggests that the GLP-1 receptor in the
hepatoportal system and in the islets of Langerhans may differ as they
show differential responsivity to GLP-1 agonists and antagonist of the
exendin family (14). Due to its profound potency in
augmenting glucose-stimulated insulin secretion, GLP-1 is likely to be
an important mediator of prandial glucose homeostasis. Better
understanding of the actions of endogenous GLP-1 and of the pathways by
which this peptide acts will hopefully enable us to fully harness the beneficial actions for the treatment of diabetes.
| |
ACKNOWLEDGEMENTS |
|---|
The expert assistance of Lori Kwasnik and Beverly Battle is gratefully acknowledged.
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: B. Balkan, Novartis Institute for Biomedical Research, LSB 3517, 556 Morris Ave., Summit, NJ 07901 (E-mail: bork.balkan{at}pharma.novartis.com).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 28 February 2000; accepted in final form 31 May 2000.
| |
REFERENCES |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
1.
Ahren, B.
Potentiators and inhibitors of insulin secretion.
Adv Mol Cell Biol
29:
175-197,
1999.
2.
Ahren, B,
and
Karlsson S.
Role of islet neuropeptides in the regulation of insulin secretion.
In: Frontiers of Insulin Secretion and Pancreatic B-Cell Research, edited by Flatt PR,
and Lenzen S.. London: Smith-Gordon, 1999, p. 313-318.
3.
Balkan, B,
and
Dunning BE.
Muscarinic stimulation maintains in vivo insulin secretion in response to glucose after prolonged hyperglycemia.
Am J Physiol Regulatory Integrative Comp Physiol
268:
R475-R479,
1995
4.
Deacon, CF,
Johnsen AH,
and
Holst JJ.
Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.
J Clin Endocrinol Metab
80:
952-957,
1995[Abstract].
5.
Deacon, CF,
Pridal L,
Klarskov L,
Olesen M,
and
Holst JJ.
Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig.
Am J Physiol Endocrinol Metab
271:
E458-E464,
1996
6.
Dunning, BE,
and
Foley JE.
New therapies to increase insulin secretion.
In: Diabetes Mellitus: A Fundamental and Clinical Text, edited by LeRoith D,
and Taylor S.. Philadelphia/New York: Lippincott-Raven, 2000, p. 836-842.
7.
Fridolf, T,
Bottcher G,
Sundler F,
and
Ahren B.
GLP-1 and GLP-1 (7-36) amide: influences on basal and stimulated insulin and glucagon secretion in the mouse.
Pancreas
6:
208-215,
1991[Web of Science][Medline].
8.
Goke, R,
Wagner B,
Fehmann HC,
and
Goke B.
Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas.
Res Exp Med (Berl)
193:
97-103,
1993[Medline].
9.
Hansen, L,
Deacon CF,
and
Holst JJ.
Glucagon-like peptide-1-(7-36) amide is transformed to glucagon-like peptide-1-(9-36) amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.
Endocrinology
140:
5356-5363,
2000
10.
Holst, JJ.
Enteroglucagon.
Annu Rev Physiol
59:
257-271,
1997[Web of Science][Medline].
11.
Holst, JJ,
and
Deacon CF.
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Diabetes
47:
1663-1670,
1998[Abstract].
12.
Nakabayashi, H,
Nishizawa M,
Nakagawa A,
Takeda R,
and
Niijima A.
Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1.
Am J Physiol Endocrinol Metab
271:
E808-E813,
1996
13.
Niijima, A.
An electrophysiological study on hepatovisceral reflex: the role played by vagal hepatic afferents from chemosensors in the hepatoportal region.
Falk Symposium
103:
159-172,
1998.
14.
Nishizawa, M,
Nakabayashi H,
Kawai K,
Ito T,
Kawakami S,
Nakagawa A,
Niijima A,
and
Uchida K.
The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor.
J Auton Nerv Syst
80:
14-21,
2000[Web of Science][Medline].
15.
Nishizawa, M,
Nakabayashi H,
Uchida K,
Nakagawa A,
and
Niijima A.
The hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-1, but not to glucose-dependent insulinotropic polypeptide, in the portal vein.
J Auton Nerv Syst
61:
149-154,
1996[Web of Science][Medline].
16.
Schjoldager, BT,
Mortensen PE,
Christiansen J,
Orskov C,
and
Holst JJ.
GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans.
Dig Dis Sci
34:
703-708,
1989[Web of Science][Medline].
17.
Strubbe, JH,
Wolsink JG,
Schutte AM,
Balkan B,
and
Prins AJ.
Hepatic-portal and cardiac infusion of CCK-8 and glucagon induce different effects on feeding.
Physiol Behav
46:
643-646,
1989[Medline].
18.
Thibault, C,
Guettet C,
Laury MC,
N'Guyen JM,
Tormo MA,
Bailbe D,
Portha B,
Penicaud L,
and
Ktorza A.
In vivo and in vitro increased pancreatic beta-cell sensitivity to glucose in normal rats submitted to a 48-h hyperglycaemic period.
Diabetologia
36:
589-595,
1993[Web of Science][Medline].
19.
Zawalich, WS,
Zawalich KC,
and
Rasmussen H.
Influence of glucagon-like peptide-1 on beta cell responsiveness.
Regul Pept
44:
277-283,
1993[Medline].
This article has been cited by other articles:
|
|
 |
|
  E. L. Raab, P. M. Vuguin, D. A. Stoffers, and R. A. Simmons Neonatal exendin-4 treatment reduces oxidative stress and prevents hepatic insulin resistance in intrauterine growth-retarded rats Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2009; 297(6): R1785 - R1794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Asarian Loss of cholecystokinin and glucagon-like peptide-1-induced satiation in mice lacking serotonin 2C receptors Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2009; 296(1): R51 - R56. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Kim and J. M. Egan The Role of Incretins in Glucose Homeostasis and Diabetes Treatment Pharmacol. Rev., December 1, 2008; 60(4): 470 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J Larsen Mechanisms behind GLP-1 induced weight loss The British Journal of Diabetes & Vascular Disease, November 1, 2008; 8(2_suppl): S34 - S41. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Tornehave, P. Kristensen, J. Romer, L. B. Knudsen, and R. S. Heller Expression of the GLP-1 Receptor in Mouse, Rat, and Human Pancreas J. Histochem. Cytochem., September 1, 2008; 56(9): 841 - 851. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Burcelin, P. D. Cani, and C. Knauf Glucagon-Like Peptide-1 and Energy Homeostasis J. Nutr., November 1, 2007; 137(11): 2534S - 2538S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Holst The Physiology of Glucagon-like Peptide 1 Physiol Rev, October 1, 2007; 87(4): 1409 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. S. Johnson, D. S. Edgerton, T. Rodewald, M. Scott, B. Farmer, D. Neal, and A. D. Cherrington Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels Am J Physiol Endocrinol Metab, October 1, 2007; 293(4): E1085 - E1091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fukaya, A. Mizuno, H. Arai, K. Muto, T. Uebanso, K. Matsuo, H. Yamamoto, Y. Taketani, T. Doi, and E. Takeda Mechanism of rapid-phase insulin response to elevation of portal glucose concentration Am J Physiol Endocrinol Metab, August 1, 2007; 293(2): E515 - E522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Ionut, I. F. Liberty, K. Hucking, M. Lottati, D. Stefanovski, D. Zheng, and R. N. Bergman Exogenously imposed postprandial-like rises in systemic glucose and GLP-1 do not produce an incretin effect, suggesting an indirect mechanism of GLP-1 action Am J Physiol Endocrinol Metab, October 1, 2006; 291(4): E779 - E785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Cani, C. Knauf, M. A. Iglesias, D. J. Drucker, N. M. Delzenne, and R. Burcelin Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like Peptide 1 receptor. Diabetes, May 1, 2006; 55(5): 1484 - 1490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Dardevet, M. C. Moore, C. A. DiCostanzo, B. Farmer, D. W. Neal, W. Snead, M. Lautz, and A. D. Cherrington Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors Am J Physiol Gastrointest Liver Physiol, November 1, 2005; 289(5): G806 - G814. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Chelikani, A. C. Haver, and R. D. Reidelberger Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2005; 288(6): R1695 - R1706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Holst and C. Orskov The Incretin Approach for Diabetes Treatment: Modulation of Islet Hormone Release by GLP-1 Agonism Diabetes, December 1, 2004; 53(suppl_3): S197 - S204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Dardevet, M. C. Moore, D. Neal, C. A. DiCostanzo, W. Snead, and A. D. Cherrington Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region Am J Physiol Endocrinol Metab, July 1, 2004; 287(1): E75 - E81. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. D'Alessio and T. P. Vahl Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E882 - E890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Meier, M. A. Nauck, D. Kranz, J. J. Holst, C. F. Deacon, D. Gaeckler, W. E. Schmidt, and B. Gallwitz Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects Diabetes, March 1, 2004; 53(3): 654 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Cupples Endo-neuro-endocrine incretin pathways Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2004; 286(2): R250 - R250. [Full Text] [PDF]
|
|
|
|
|
|
B. Ahren Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2004; 286(2): R269 - R272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Prigeon, S. Quddusi, B. Paty, and D. A. D'Alessio Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect Am J Physiol Endocrinol Metab, October 1, 2003; 285(4): E701 - E707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nishizawa, M. C. Moore, M. Shiota, S. M. Gustavson, W. L. Snead, D. W. Neal, and A. D. Cherrington Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs Am J Physiol Endocrinol Metab, May 1, 2003; 284(5): E1027 - E1036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Burcelin, A. Da Costa, D. Drucker, and B. Thorens Glucose Competence of the Hepatoportal Vein Sensor Requires the Presence of an Activated Glucagon-Like Peptide-1 Receptor Diabetes, August 1, 2001; 50(8): 1720 - 1728. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
) or jugular vein (
) on the insulin
response (A) and glucose excursion (B) to a
portal glucose bolus [control represents glucose + vehicle
(
)]. C: the effects of GLP-1 administered
intravenously or via portal vein on plasma insulin concentrations in
the absence of exogenous glucose. Data represent means ± SE. *P < 0.05, ***P < 0.001 vs. control.
